Pharmacokinetics, Efficacy, Tolerability and Safety of a New Subcutaneous Human Immunoglobulin 16.5% in Primary Immune Deficiency

被引：0

作者：

Kobayashi, Roger ^{[1
]}

Gupta, Sudhir ^{[2
,3
]}

Melamed, Isaac R. ^{[4
]}

Mandujano, Jose F. ^{[5
]}

Kobayashi, Ai Lan ^{[6
]}

Ritchie, Bruce ^{[7
]}

Turpel-Kantor, Eva ^{[8
]}

Litzman, Jiri ^{[9
]}

机构：

[1] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA

[2] Univ Calif Irvine, Pathol & Lab Med, Med, Irvine, CA USA

[3] Univ Calif Irvine, Microbiol & Mol Genet, Irvine, CA USA

[4] IMMUNOe Res Ctr Centennial, Denver, CO USA

[5] Pediat Pulm Associates North TX, Frisco, PA USA

[6] Midlands Pediat, Papillion, NE 68046 USA

[7] Univ Alberta, Div Hematol, Dept Med, Fac Med & Dent, Edmonton, AB, Canada

[8] Octapharma Pharmazeutika Produktionsges MbH, Immunol, Vienna, Austria

[9] St Annes Univ Hosp, Dept Clin Immunol Allergol, Immunol, Brno, Czech Republic

来源：

JOURNAL OF CLINICAL IMMUNOLOGY | 2018年 / 38卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

128

引用

页码：391 / 392

页数：2

共 50 条

[1] Long-Term Safety, Efficacy, and Tolerability of Subcutaneous Human Immunoglobulin 16.5% in Patients with Primary Immunodeficiencies
Gupta, Sudhir
Kobayashi, Roger
Melamed, Isaac
Rehman, Syed
Kobayashi, Ai
Mandujano, jose-Fernando
Geng, Bob
Ritchie, Bruce
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB76 - AB76
[2] Medium-to-Long-Term Safety, Efficacy, and Tolerability of Subcutaneous Human Immunoglobulin 16.5% in Patients with Primary Immunodeficiencies
Rizvi, Syed
Gupta, Sudhir
Kobayashi, Roger
Kobayashi, Ai Lan
Melamed, Isaac
Mandujano, Jose Fernando
Geng, Bob
Rehman, Syed
Ritchie, Bruce
Young, Shardae
JOURNAL OF CLINICAL IMMUNOLOGY, 2021, 41 (SUPPL 1) : S101 - S101
[3] Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies
Kobayashi, Roger H.
Gupta, Sudhir
Melamed, Isaac
Mandujano, J. Fernando
Kobayashi, Ai Lan
Ritchie, Bruce
Geng, Bob
Atkinson, Thomas Prescott
Rehman, Syed
Turpel-Kantor, Eva
Litzman, Jiri
FRONTIERS IN IMMUNOLOGY, 2019, 10
[4] Efficacy, Tolerability and Safety of Cutaquig®, a New Subcutaneous Human Immunglobulin 16.5% in Adult Patients with Primary Immunodeficiencies
Latysheva, E.
Rodina, Y.
Sizyakina, L.
Totolian, A.
Tuzankina, I
JOURNAL OF CLINICAL IMMUNOLOGY, 2019, 39 : S64 - S65
[5] Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies
Kobayashi, Roger H.
Litzman, Jiri
Melamed, Isaac
Mandujano, J. Fernando
Kobayashi, Ai Lan
Ritchie, Bruce
Geng, Bob
Atkinson, T. Prescott
Rehman, Syed
Hoeller, Sonja
Turpel-Kantor, Eva
Kreuwel, Huub
Speer, J. C.
Gupta, Sudhir
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2022, 210 (02): : 91 - 103
[6] Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency
Niebur, H. B.
Duff, C. M.
Shear, G. F.
Nguyen, D.
Alberdi, T. K.
Dorsey, M. J.
Sleasman, J. W.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2015, 181 (03): : 441 - 450
[7] Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens
Sudhir Gupta
James DeAngelo
Isaac Melamed
Jolan E. Walter
Ai-Lan Kobayashi
Tracy Bridges
J. Wesley Sublett
Jonathan A. Bernstein
Alan Koterba
Michael Manning
Joanna Maltese
Sonja Hoeller
Eva Turpel-Kantor
Huub Kreuwel
Roger H. Kobayashi
Journal of Clinical Immunology, 2023, 43 : 1414 - 1425
[8] Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens
Gupta, Sudhir
DeAngelo, James
Melamed, Isaac
Walter, Jolan E. E.
Kobayashi, Ai-Lan
Bridges, Tracy
Sublett, J. Wesley
Bernstein, Jonathan A. A.
Koterba, Alan
Manning, Michael
Maltese, Joanna
Hoeller, Sonja
Turpel-Kantor, Eva
Kreuwel, Huub
Kobayashi, Roger H. H.
JOURNAL OF CLINICAL IMMUNOLOGY, 2023, 43 (06) : 1414 - 1425
[9] Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Human Immunoglobulin 16.5% Administered at Modified Dosing Regimens in Patients with Primary Immunodeficiency Diseases - Study Design
Melamed, Isaac
Gupta, Sudhir
Kobayashi, Roger
Eppolito, Michael
Maltese, Joanna
Rizvi, Syed
Kobayashi, Ai
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB75 - AB75
[10] Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies (vol 10, 40, 2019)
Kobayashi, Roger H.
Gupta, Sudhir
Melamed, Isaac
Mandujano, J. Fernando
Kobayashi, Ai Lan
Ritchie, Bruce
Geng, Bob
Atkinson, Thomas Prescott
Rehman, Syed
Turpel-Kantor, Eva
Litzman, Jiri
FRONTIERS IN IMMUNOLOGY, 2022, 13

← 1 2 3 4 5 →